Compounded Semaglutide Poses Significant Safety Concerns

Recent studies and FDA warnings have underscored substantial safety issues associated with compounded versions of semaglutide. These concerns primarily involve inconsistent potency and potential contamination, which are not typically found in FDA-approved GLP-1 medications. Reports indicate adverse events such as incorrect dosing and severe gastrointestinal problems linked to these non-approved formulations.